A "WARNING" SIGN IS RAISED IN LOW-RISK TAVR PATIENTS AFTER CONDUCTING META-ANALYSIS
Data from six studies indicate that whereas short-run mortality is comparable between TAVR and SAVR, a lot more of low-risk patients who have TAVR die by a couple of years.​

RIVAROXABAN FOR CV EVENT REDUCTION IN CAD AND PAD PATIENTS IS ACCEPTED BY FDA
The extension changes the attention to aiming “atherothrombosis” in certain patients with chronic stable disease.

​